The global diabetic macular edema (DME) market isprojected to register a sluggish expansion at 1.1% CAGR through 2027, according
to a report by Future Market Insights (FMI). The report estimates the market to
reach US$ 3710.2 Mn in 2017; by 2027 this number is expected to surpass US$ 4,100
Mn.
An Uptake of Intravitreal Implants by Patients to DriveGrowth of the Market in North America
North America will remain dominant in the global diabeticmacular edema market. An uptake of intravitreal implants by new as well as
existing patients, who do not show any improvement post-treatment with
intravitreal injections, is expected to sustain growth of the market in this
region.
Although control of diabetes is a health priority indeveloped North American countries, such as the U.S., less attention is given
to DME management, with diabetes-related caregivers tending to focus on
treatment of diabetic complications. A major reason behind this is lack of
effective treatment for DME in North America. In addition, an error exists
between industry sponsored and independently run clinical trials. Most of the
independent clinical trials for DME treatment lack long-term results pertaining
to safety and efficacy of new combination therapies for DME. These factors are
likely to inhibit growth of the market in North America.
Diabetic Macular Edema Market in Western Europe toRegister the Highest CAGR through 2027
The diabetic macular edema market in Western Europe isexpected to register a comparatively higher CAGR than other region segments
through 2027. Pharmaceutical companies in this region are making substantial
investments in research and development, new technologies, and infrastructure
in order to capture a market share in the surging burden of eye diseases. This
is expected to retain growth of the market in Western Europe.
However, patients in Western Europe resist the intake ofintravitreal injections of anti-VEGF drugs, which leads to an instant increase
in intraocular pressure causing severe pain in the head or eyes. This a major
factor impeding growth of the diabetic macular edema market in Western Europe.
Anti-VEGF will Remain Preferred Product in the GlobalDiabetic Macular Edema Market
Anti-VEGF will remain preferred product in the market, withsales estimated to expand at 1% CAGR through 2027. Eylea will continue to be
the most lucrative anti-VEGF drug in the market. However, demand for
corticosteroids will remain comparatively lower than anti-VEGF during the
forecast period.
By product form, intravitreal injections will continue to besought-after in the market, with sales poised to surpass US$ 4,000 Mn by
2027-end. Sales of intravitreal implants will register a comparatively higher
CAGR than intravitreal injections through 2027.
Hospital pharmacy is estimated to remain the largestdistribution channel in the market, as majority of countries across the globe
dispense intravitreal injections and implants to outpatients by hospital
pharmacies. Retail pharmacy, which mainly provides aliquots of off-label
indications such as Avastin prescription, will register a comparatively low
CAGR than hospital pharmacy in the market through 2027.
Key market players identified in FMI’s report includeNovartis AG, Bayer AG, Allergan Plc., F. Hoffman-La Roche Ltd., Alimera
Sciences Inc., Valeant Pharmaceuticals International, Inc. (Bausch & Lomb
Inc.)
Key Segments:
- By Therapy Type:
- Anti-VEGF
- Ranibizumab (Lucentis)
- Afilbercept (Eylea)
- Corticosteroids
- Fluocinolone Acetonide (Iluvien)
- Dexamethasone (Ozurdex)
- Other Off-label Drugs (Triamcinolone Acetonide, Bevacizumab
and Pegaptanib) - By Product Form:
- Intravitreal Injections
- Intravitreal Implants
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Others
- By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- APEJ
- Japan
- MEA
Information Source:
